Evidence map›Paper›PMID 34994587›Full record

ArticleJCO precision oncology2021

Pursuing Better Biomarkers for Immunotherapy Response in Cancer Through a Crowdsourced Data Challenge.

Benjamin G Vincent, Joseph D Szustakowski, Parul Doshi, Michael Mason, Justin Guinney, David P Carbone

Abstract read
In one paragraph

Article in JCO precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. The Future of Precision Oncology.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Benjamin G VincentDepartment of Medicine, Division of Hematology/Oncology, Department of Microbiology and Immunology, Curriculum in Bioinformatics and Computational Biology, Computational Medicine Program, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Joseph D SzustakowskiBristol Myers Squibb, Princeton, NJ.
Parul DoshiBristol Myers Squibb, Princeton, NJ.
Michael MasonSage Bionetworks, Seattle, WA.
Justin GuinneySage Bionetworks, Seattle, WA.
David P CarboneThe Ohio State University Comprehensive Cancer Center, Columbus, OH.

Funding

Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation.R37CA247676 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VINCENT, BENJAMIN G · 2020 to 2025
$3.6M
NCI NIH HHS R37 CA247676
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biomarkers, TumorClinical Trials as TopicCrowdsourcingHumansImmune Checkpoint InhibitorsImmunotherapyModels, BiologicalNeoplasmsNivolumabBiomarkers, TumorImmune Checkpoint InhibitorsNivolumab

Identifiers

PMID34994587
PMCPMC9848594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.